Search results
Newswise Expert | Jonathan Dowell, UT Southwestern Medical Center
Newswise· 6 hours agoJonathan Dowell, M.D., is a Professor in the
Gene therapy offers huge potential for combating disease, doctors say
United Press International via Yahoo News· 20 hours agoResearchers are engineering ways to alter genes or swap flawed ones with healthy replacements,...
The One Food an Oncologist Never, Ever Eats
Parade· 7 days agoHere’s how to eat with cancer prevention in mind. The American Institute for Cancer Research and the World Cancer Research Fund estimate that between 30...
Faulty gene likely to be cause of severe learning difficulties, study finds
The Telegraph via Yahoo News· 11 hours agoA faulty gene is likely to be responsible for many severe learning difficulties, scientists believe...
EXCLUSIVE: Telo Genomics' Smoldering Multiple Myeloma Prognostic Test Predicts Risk Of Disease...
Benzinga via Yahoo Finance· 2 days agoThe published study included a total of 168 smoldering multiple myeloma patients. The article...
Halia Therapeutics to Participate at BIO International Convention and The European Hematology...
The Herald Journal· 3 days agoPreliminary safety, efficacy, and biomarker data from the ongoing Phase II trial evaluating HT-6184 in MDS patients will be presented at the EHA 2024 Hybrid Congress.
Autolus shares hold steady with Buy rating on Obe-cel market penetration By Investing.com
Investing.com· 1 day agoOn Thursday, Truist Securities maintained a Buy rating on shares of Autolus Therapeutics Plc...
Citi bullish on Legend Biotech stock, positive on sales growth By Investing.com
Investing.com· 19 hours agoOn Friday, Citi reaffirmed its confidence in Legend Biotech Corp (NASDAQ:LEGN), stock maintaining a...
Unprecedented PFS Results in ALK-Positive Lung Cancer Trial
MedPage Today· 1 day agoFive-year results from a phase III trial had experts gushing over lorlatinib's (Lorbrena)...
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By...
Investing.com· 1 day agoIn their first quarter 2024 earnings call, Cellectis, a biopharmaceutical company, presented a...